Hartland asked "Did they present there yet. If so did they publish slides?"

Yes they finished their presentations on Sunday and Monday according to the scheduled detailed in the news release. Two posters and one oral presentation at the ERA-EDTA conference and one sponsored industry satellite symposium entitled "Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?"

Consistent to what was already stated in the news release, the two posters are up on the Resverlogix publications page. The news release also stated that the symposium presentations will be made available at: http://pace-cme.org/bet-inhibition/ sometime in the future. However, there was a lag period of several days (maybe a few weeks, I can't remember for sure) during the pace-cme symposium at ESC 2016 last August, so there will probably be a similar lag period for this symposium. I don't think there are plans to publish the slides from the other oral presenation.

Here are the direct links to the 2 posters:

European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress 2017: Effects of Apabetalone (RVX-208) on Serum Albumin in Subjects with CVD, Diabetes and Chronic Kidney Disease; a Post-Hoc Analysis of the ASSURE and SUSTAIN Clinical Trials. Authors: Ewelina Kulikowski, Christopher Halliday, Ken Lebioda, Jan Johansson, Michael Sweeney and Kamyar Kalantar-Zadeh.

ERA-EDTA Poster Link 1

ERA-EDTA Congress 2017: Apabetalone, A Bromodomain and Extraterminal Protein Inhibitor, Decreases Key Factors in Vascular Calcification in Vitro and in Clinical Trials. Authors: Ewelina Kulikowski, Dean Gilham, Laura Tsujikawa, Sylwia Wasiak, Christopher Halliday, Brooke Rakai, Kamyar Kalantar-Zadeh, Ravi Jahagirdar, Mike Sweeney, Jan Johansson, Norman C.W. Wong, Richard Robson.

ERA-EDTA Poster Link 2